EECP is an enhanced external counterpulsation. It is cost effective, non invasive, non surgical, non pharmaceutical, out patient therapy for Angina, Heart attack and heart failure patients. It is FDA (USA) and NHS (UK) approved.
How is EECP Performed?
During EECP Patient lies on bed of machine. Three or five electrodes are applied to the chest to record a constant ECG. A Plethysmograph is applied to index finger to record a tracing that represents blood pressure and oxygen saturation. Set of 3 4 cuffs is wrapped around the calves, thighs and buttocks. EECP system uses an ECG signal to electronically synchronize inflation and deflation of the cuffs.
Multiple Presentations at the European Society of Cardiology Congress Document EECP Promotes Coronary Collateral Flow Leading to Sustained Clinical Improvement
Press Release Source: Vasomedical, Inc. On Tuesday September 1, 2009, 9:55 am EDT
WESTBURY, N.Y.–(BUSINESS WIRE)–Vasomedical, Inc. (“Vasomedical”) (OTC: VASO - News), a world leader in the noninvasive treatment of cardiovascular diseases, today announced that evidence presented by Dr. Eva-Elina Buschmann on behalf of the European Arteriogenesis Network 2 Trial, at the 2009 European Society of Cardiology (ESC) Congress taking place in Barcelona, Spain, demonstrates that EECP® therapy along with its positive acute hemodynamic benefits also promotes the growth of coronary collateral blood vessels to ischemic regions improving circulation in patients with stable angina.
When it came to charting a path for her breast cancer treatment, Kathy Sabadosa, 43, realized she’d rather preserve a lifestyle of skiing, running, biking, and caring for two young kids than save her figure. After her diagnosis two years ago, Sabadosa’s first inclination was to have her whole breast removed and to undergo reconstructive surgery. But after her surgeon drew Sabadosa out about her priorities and how she might handle reconstruction’s possible side effects (arm swelling, shoulder problems, scarring around an implant), she decided to skip that step. “My arm and shoulder functioning was much more important to me,” says Sabadosa, who lives in Norwich, Vt.
Evidence keeps on coming out that stents, drug eluding or not, just are not helpful in most cases. Elective angioplasty/stenting needs to stop, and stop now. Just like the commercial for using illegal drugs, JUST SAY NO!
The FBI is apparently investigating allegations that a Maryland cardiologist, Dr. John “Jack” McLean was performing unnecessary stent implantations on his patients. Officials have stated that most of the patients involved are Medicare patients. On average, Medicare pays between $11,184 to $14,287 for a drug-eluting stent procedure. The investigation which involves the FBI as well as the Health and Human Services involves whether the procedures were medically necessary and whether alternative methods could have been used to treat blood clots. Dr. McLean has stated that he has done no wrong and none of his patients are complaining.
POSTED BY: Steve Parker | June 30, 2009 | 11:37 AM
Cardiologist Mehmood M. Patel was recently sentenced to 10 years in federal prison for healthcare fraud in Louisiana. He was performing unnecessary procedures such as deploying balloons and stents in heart arteries through catheters, in arteries that had little or insigificant blockage. He also falsified patient patient symptoms in medical records and falsified findings on medical tests.
“When your arteries narrow, so does your life,” says a TV ad from Johnson & Johnson. “It’s time to open it up.”
Cue the kaleidoscopic image of the company’s Cypher drug-coated stent. And then come the shots of remarkably buff people, presumably with Cypher stents, doing things we couldn’t even dream of trying in our relatively healthy state, like swimming long distance in open water under a cloudy, threatening sky.
Title: Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D — Presented at AHA 2009) Trial Sponsor: National Institutes of Health (National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases), GlaxoSmithKline, Lantheus, Medical Imaging, Astellas Pharma, Merck, Abbott Laboratories, Pfizer, Medisense, Bayer, Becton Dickinson, JR Carlson Labs, Centocor, Eli Lilly, LipoScience, Novartis, Novo Nordisk Year Published 2009 Topic(s): Cardiovascular Surgery, General Cardiology, Interventional Cardiology Summary Posted: 11/17/2009 9:00:00 AM Writer:Ajay J. Kirtane, M.D., F.A.C.C. Author Disclosure: Consultant Fees/Honoraria: Medicure; Consultant Fees/Honoraria: Danube Pharmaceuticals; Consultant Fees/Honoraria: Medicines Company; Consultant Fees/Honoraria: St. Jude Medical; Consultant Fees/Honoraria: Medtronic CardioVascular; Consultant Fees/Honoraria: Abbott Vascular Reviewer:Anthony A. Bavry, M.D., M.P.H., F.A.C.C. Author Disclosure: This author has nothing to disclose. Supplemental Reviewer:Deepak L. Bhatt, M.D., F.A.C.C. Author Disclosure: Research/Research Grants: Eisai; Research/Research Grants: Heartscape; Research/Research Grants: Ethicon; Research/Research Grants: Bristol Myers Squibb; Research/Research Grants: Sanofi Aventis; Research/Research Grants: The Medicines Company
Printer Friendly
